Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 22nd Annual Global Investment Conference

Rhea-AI Summary

Verrica Pharmaceuticals (VRCA) announced that CEO Ted White will present a business overview at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 2:00 p.m. ET. The conference will be held virtually, and attendees can access the live webcast on Verrica's website. The company is developing VP-102, a potential first-in-class therapy for molluscum contagiosum, for which an NDA was submitted in September 2019. A Complete Response Letter from the FDA was received on July 13, 2020, regarding this NDA.

Positive

• VP-102 has potential to be the first-in-class topical therapy for molluscum contagiosum.
• Company completed a Phase 2 study of VP-102 for common warts and is conducting another Phase 2 study for external genital warts.

Negative

• Received a Complete Response Letter from the FDA regarding the NDA for VP-102 on July 13, 2020.

WEST CHESTER, Pa., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the H.C. Wainwright 22^nd Annual Global Investment Conference, taking place virtually on Tuesday, September 15, 2020, at 2:00 p.m. ET.

A live webcast of the event can be accessed in the Investors/Presentations & Events section of the Verrica website at http://www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days. 

About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. The Company’s late-stage product candidate, VP-102, is a potential first-in-class topical therapy for the treatment of molluscum contagiosum. Verrica submitted an NDA for VP-102 for the treatment of molluscum in September 2019. A Complete Response Letter was received from the FDA regarding the NDA for VP-102 on July 13, 2020. If approved, VP-102 will be marketed in the United States under the conditionally accepted brand name YCANTH™.  In addition, Verrica has successfully completed a Phase 2 study of VP-102 for the treatment of common warts and is currently conducting a Phase 2 study of VP-102 for the treatment of external genital warts. The Company is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts.  For more information, visit www.verrica.com.

FAQ

What is the significance of the H.C. Wainwright conference for Verrica Pharmaceuticals (VRCA)?

CEO Ted White will present a business overview, which may attract investor interest.

What is the status of VP-102 from Verrica Pharmaceuticals (VRCA)?

VP-102 is under FDA review following a Complete Response Letter received on July 13, 2020.

When will the H.C. Wainwright conference take place for VRCA?

The conference will occur on September 15, 2020, at 2:00 p.m. ET.

What is VP-102 and its therapeutic purpose?

VP-102 is a topical therapy under development for the treatment of molluscum contagiosum.